(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of -0.41% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Becton Dickinson & Co's revenue in 2026 is $20,840,000,000.On average, 17 Wall Street analysts forecast BDX's revenue for 2026 to be $5,308,818,732,000, with the lowest BDX revenue forecast at $5,138,576,982,000, and the highest BDX revenue forecast at $5,533,810,228,800. On average, 17 Wall Street analysts forecast BDX's revenue for 2027 to be $5,419,952,546,400, with the lowest BDX revenue forecast at $5,229,009,399,600, and the highest BDX revenue forecast at $5,664,828,279,600.
In 2028, BDX is forecast to generate $5,625,332,193,600 in revenue, with the lowest revenue forecast at $5,408,239,914,000 and the highest revenue forecast at $5,892,271,257,600.